Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + bevacizumab + albumin-bound paclitaxel + cisplatin
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This experimental combination regimen is being investigated as an induction therapy for high-risk locally advanced nasopharyngeal carcinoma (NPC). It consists of the PD-1 inhibitor sintilimab, the anti-VEGF monoclonal antibody bevacizumab, and a chemotherapy backbone of albumin-bound paclitaxel (nab-paclitaxel) and cisplatin (TP chemotherapy). The regimen is designed to improve outcomes in patients with N2-N3 stage disease, who often show limited benefit from standard chemo-immunotherapy. By combining immune checkpoint inhibition with anti-angiogenic therapy and cytotoxic chemotherapy, the treatment aims to reduce tumor burden and decrease the risk of local recurrence and distant metastasis before definitive chemoradiotherapy.
- Other names
- Sintilimab + Bevacizumab + TP InductionSintilimab + Bevacizumab + nab-paclitaxel + cisplatinSintilimab + Bevacizumab + TP Induction for High-Risk NPC
02
Targets
TUBB (Tubulin (alpha and beta subunits))SPARC (Secreted protein acidic and rich in cysteine)gp60 (GP60 Receptor)DNAPDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on sintilimab + bevacizumab + albumin-bound paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + bevacizumab + albumin-bound paclitaxel + cisplatin.